Abstract

The gaining popularity of tobacco and nicotine delivery products, such as electronic cigarettes (e-cigarettes) being perceived as relatively safe is of a medical concern. The long-term safety of these new products remains uncertain for oral health. In this study, in vitro effects of e-liquid were assessed in a panel of normal oral epithelium cell lines (NOE and HMK), oral squamous cell carcinoma (OSCC) human cell lines (CAL27 and HSC3), and a mouse oral cancer cell line (AT84) using cell proliferation, survival/cell death, and cell invasion assays. In addition, signaling pathways underlying the pro-invasive activity of e-cigarettes were evaluated by gene and protein expression analysis. We demonstrated that e-liquid promotes proliferation and anchorage-independent growth of OSCC and induces morphological changes associated with enhanced motility and invasive phenotypes. Furthermore, e-liquid-exposed cells express significantly reduced cell viability, regardless of e-cigarette flavour content. At the gene expression level, e-liquid induces changes in gene expression consistent with epithelial to mesenchymal transition (EMT) revealed by reduced expression of cell epithelial markers such as E-cadherin and enhanced expression of mesenchymal proteins like vimentin and B-catenin seen both in OSCC cell lines and normal oral epithelium cells. In summary, the ability of e-liquid to induce proliferative and invasive properties along the activation of the EMT process can contribute to the development of tumorigenesis in normal epithelial cells and promote aggressive phenotype in pre-existing oral malignant cells.

Details

Title
E-liquid alters oral epithelial cell function to promote epithelial to mesenchymal transition and invasiveness in preclinical oral squamous cell carcinoma
Author
de Lima, Jefferson Muniz 1 ; Macedo, Carolina Carneiro Soares 2 ; Barbosa, Gabriela Vasconcelos 3 ; Castellano, Lúcio Roberto Cançado 4 ; Hier, Michael P. 5 ; Alaoui-Jamali, Moulay A. 6 ; da Silva, Sabrina Daniela 2 

 McGill University, Department of Otolaryngology Head and Neck Surgery, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); McGill University, Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Faculty of Medicine, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Federal University of Paraiba (UFPB), Department of Oral Pathology, Faculty of Dentistry, João Pessoa, Brazil (GRID:grid.411216.1) (ISNI:0000 0004 0397 5145) 
 McGill University, Department of Otolaryngology Head and Neck Surgery, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); McGill University, Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Faculty of Medicine, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
 McGill University, Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Faculty of Medicine, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Federal University of Paraiba (UFPB), Department of Oral Pathology, Faculty of Dentistry, João Pessoa, Brazil (GRID:grid.411216.1) (ISNI:0000 0004 0397 5145) 
 McGill University, Department of Otolaryngology Head and Neck Surgery, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649); Federal University of Paraíba, Human Immunology Research and Education Group, João Pessoa, Brazil (GRID:grid.411216.1) (ISNI:0000 0004 0397 5145); Federal University of Paraíba, Graduate Program in Dentistry, João Pessoa, Brazil (GRID:grid.411216.1) (ISNI:0000 0004 0397 5145) 
 McGill University, Department of Otolaryngology Head and Neck Surgery, Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
 McGill University, Segal Cancer Centre and Lady Davis Institute for Medical Research, Sir Mortimer B. Davis-Jewish General Hospital, Departments of Medicine, Oncology, and Pharmacology and Therapeutics, Faculty of Medicine, Montreal, Canada (GRID:grid.14709.3b) (ISNI:0000 0004 1936 8649) 
Pages
3330
Publication year
2023
Publication date
2023
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2780269320
Copyright
© The Author(s) 2023. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.